CEB-01

CEB-01 is a drug-eluting membrane. Surgeons place it in the tumor bed after resection of abdominal cancers, where it slowly releases SN-38 (the active metabolite of irinotecan) directly into tissue most likely to harbor microscopic residual disease. The pitch is simple: deliver a potent chemotherapy locally where it kills escaping cancer cells, and avoid the systemic toxicity that limits irinotecan dosing by IV. CEBIOTEX, a privately held Spanish biotech (spun out of the Universitat Politècnica de Catalunya INTEXTER textile institute and the Parc Científic de Barcelona), moved CEB-01 through Phase 1 in adult retroperitoneal soft tissue sarcoma (NCT04619056, n=21, completed) [1], with first-in-human results reportedly published in Annals of Surgical Oncology in 2026 [2, unverified citation]. The company is now running a Phase 2 trial in pediatric patients with locally resectable abdominal tumors (NCT06986811, n=60, recruiting) [3], plus an exploratory trial in resectable pancreatic adenocarcinoma (NCT06538857, n=39, PLGA membrane formulation, recruiting) [4]. CEB-01 has EMA Orphan Drug Designation in both soft tissue sarcoma and pancreatic cancer [5]. This is a device-drug combination at the surgical-oncology interface, not a conventional small molecule or systemic antibody.

CEB-01 is a novel investigational product, never approved anywhere. The scientific novelty is not the payload (SN-38 is a decades-old TOP1 poison already delivered via irinotecan) but the delivery format: a biocompatible electrospun PLGA (poly-lactic-co-glycolic acid) nanofiber membrane that releases drug locally from a surgical implant site. Current status by trial: pediatric Phase 2 recruiting in abdominal tumors (NCT06986811, n=60) [3], adult pancreatic cancer exploratory trial recruiting (NCT06538857, n=39, primary completion September 2028 per ClinicalTrials.gov) [4], and the completed Phase 1 safety study in retroperitoneal sarcoma (NCT04619056, n=21) [1] that established the recommended Phase 2 dose and reportedly generated a Gonzalez et al. Ann Surg Oncol 2026 publication [2, PMID 41998462 flagged as unverified at time of writing]. The sponsor has EMA Orphan Drug Designation in STS and in pancreatic cancer [5], and historical funding from Horizon 2020 plus a €4M Series A in 2020 led by Inveready/Capital Cell/Ship2B [6]. No FDA breakthrough, fast track, orphan, or RMAT designations are publicly recorded, and the regulatory posture is EMA-first. The pediatric Phase 2 primary endpoint is frequency of adverse events, which pegs the near-term readout as safety and tolerability rather than an efficacy benchmark. Rough timeline estimate: given n=60 pediatric enrollment across multiple tumor types at a small-sponsor pace, a safety primary readout is realistic in the 2028 to 2030 window, with any recurrence-based efficacy data a further 3 to 5 years out.

SN-38 inhibits topoisomerase I (TOP1), an enzyme that nicks, unwinds, and reseals DNA so that replication and transcription machinery can move through supercoiled chromosomes. Think of TOP1 as a controlled relief valve for DNA tension. When SN-38 traps TOP1 mid-cut, those single-strand breaks don't get resealed, and in dividing cells they convert into lethal double-strand breaks. Rapidly dividing cells (cancer, gut lining, bone marrow) die first. SN-38 is roughly 100 to 1000 times more potent than irinotecan [7], but it has terrible solubility and cannot be dosed intravenously as a free drug, which is why irinotecan (a prodrug slowly converted to SN-38 in the liver) is what the clinic actually uses. CEB-01 flips the problem: embed SN-38 in a slow-release polymer, place it directly in the surgical cavity after tumor removal, and deliver high local concentrations to the margins where microscopic residual cells live. The membrane is an electrospun PLGA nanofiber mat; SN-38 is released primarily via hydrolytic degradation of the PLGA matrix combined with diffusion from the fiber surface, with sustained release reported over several days in preclinical pancreatic cancer models [8]. Detailed in-human release kinetics are not yet published. TOP1 as a target is deeply validated: irinotecan, topotecan, and a wave of TOP1-payload antibody-drug conjugates (Enhertu, Trodelvy, Dato-DXd) are all built on this mechanism [9]. The genuine question for CEB-01 is not whether SN-38 kills cancer cells (it does) but whether loco-regional delivery meaningfully reduces recurrence over standard surgery alone without wrecking wound healing.

NCT06986811 is a single-arm Phase 2 study in pediatric patients with locally resectable abdominal tumors, enrolling 60 participants, sponsored by CEBIOTEX [3]. The primary endpoint is frequency of adverse events, so the readout will be about tolerability in children, not an efficacy benchmark. There is no randomized comparator arm. Pediatric abdominal tumors are heterogeneous: Wilms tumor, neuroblastoma, rhabdomyosarcoma, hepatoblastoma, and others all qualify in principle, each with different biology, different standards of care, and different baseline recurrence rates. Pooling them for a safety endpoint is reasonable; pooling them for an efficacy claim would not be. The adult Phase 1 in retroperitoneal sarcoma (NCT04619056, n=21, completed) established the recommended Phase 2 dose and showed the implant was surgically tolerable [1]. The pancreatic cancer trial (NCT06538857, n=39) [4] is described on ClinicalTrials.gov as an exploratory study of safety, tolerability, efficacy, and pharmacokinetics of the CEB-01 PLGA membrane in resectable disease, positioned closer to a Phase 1b or Phase 1/2 hybrid than a classical early Phase 1 given the enrollment size and PK/efficacy co-endpoints. Across all three trials, enrollment is modest and open-label, and recurrence endpoints will require years of post-surgical follow-up. The design is appropriate for a device-drug combination at this stage; it is not designed to generate approval-grade efficacy data for the pediatric indication.

Our model estimates a 4% chance this drug is eventually approved. It starts from the historical base rate for Phase 2 drugs in this area (about 13%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by a non-randomized design and more secondary endpoints than usual; it is held back by the sponsor's thin or weak approval record and weak or limited earlier-phase results. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk is the biggest unknown. Historical local recurrence in retroperitoneal sarcoma is grim: TARPSWG registry and multiple cohort analyses place 5-year local recurrence around 45 to 50%, with first-local-recurrence cohorts hitting roughly 59% at 6 years [10]. So the bar is low in that indication, but pediatric abdominal tumors are a heterogeneous mix. A membrane that reduces sarcoma recurrence may not help neuroblastoma or hepatoblastoma, which have different biology and different adjuvant chemo regimens already in use. The Phase 2 single-arm design forces any efficacy claim to lean on historical controls, which is weak evidence. Safety risk: SN-38 is a potent chemotherapeutic. Even delivered locally, it can cause impaired wound healing, anastomotic leak in bowel-adjacent cases (a failure of surgically rejoined bowel segments to seal at the suture line, which can spill intestinal contents into the abdominal cavity and is potentially fatal), fistula formation, local inflammation, and secondary infection. The Phase 1 enrolled only 21 adults [1], which misses rare adverse events. Pediatric safety is a separate question because developing tissues respond differently to cytotoxic exposure. Execution risk: CEBIOTEX is a small privately held Spanish company with one program, modest disclosed funding (last public round €4M Series A in 2020 [6]), and a 60-patient pediatric trial recruiting across multiple tumor types. Slow enrollment is likely and additional fundraising is almost certainly required to carry the pancreatic program through readout. Commercial risk: this is a surgical adjunct, so pricing is capped by hospital procurement and surgical reimbursement codes, and the addressable market is narrow (surgically resected locally advanced abdominal cancers). Competitive landscape, properly scoped to loco-regional delivery: HIPEC (hyperthermic intraperitoneal chemotherapy, a warmed cisplatin/mitomycin lavage of the open abdomen) and PIPAC (pressurized intraperitoneal aerosol chemotherapy, delivered by laparoscopic aerosolization) are the real competitors in the abdominal cavity, with HIPEC already in routine use for peritoneal carcinomatosis in colorectal, ovarian, and appendiceal cancers. CEB-01's differentiation is a solid implant with multi-day release at the tumor bed rather than a one-shot lavage of the entire cavity. Systemic TOP1 strategies (ADCs from Daiichi Sankyo and AstraZeneca, including Enhertu and Dato-DXd) hit the same target but address a different clinical question (systemic micrometastasis), so they are adjacent rather than direct competitors [9].

CEB-01 is worth watching for the sarcoma signal, not large enough to drive portfolio allocation. The specific data point to track: local recurrence rates in the completed Phase 1 retroperitoneal sarcoma cohort (NCT04619056, n=21) [1] with meaningful follow-up. The Gonzalez et al. Ann Surg Oncol 2026 reference [2] has not been independently verified at the PMID level in this writeup, so any downstream claims about the Phase 1 recurrence numbers should be held in abeyance until the paper is confirmed and the data extracted. If local recurrence drops by a wide margin versus TARPSWG and SEER (the NIH Surveillance, Epidemiology, and End Results national cancer outcomes database) sarcoma baselines with acceptable wound-healing safety, CEB-01 becomes a credible loco-regional delivery platform and raises the question of whether other payloads (not just SN-38) could be deployed in the same PLGA membrane. The closest structural precedent is GLIADEL (carmustine wafer), FDA-approved for recurrent GBM in 1997 and newly diagnosed high-grade glioma in 2003 [11]. GLIADEL demonstrates that a drug-eluting surgical implant can clear FDA, but it also demonstrates the commercial ceiling: niche surgical adjunct, modest adoption, limited pricing power. The pediatric Phase 2 (NCT06986811) [3] readout is 2 to 4 years away and safety-first, so it is not a near-term inflection. The pancreatic cancer trial (NCT06538857) [4] is in resectable disease, which is a small slice of pancreatic cancer and still exploratory. CEBIOTEX is privately held, so there are no equity comps to anchor commercial expectations, and the program has no public licensing or partnership deals disclosed. Check back when: (1) the Ann Surg Oncol 2026 paper is verified and recurrence numbers are compared against TARPSWG/SEER sarcoma baselines, (2) CEBIOTEX announces initial pancreatic Phase 1 safety or feasibility data, or (3) CEBIOTEX closes a Series B or announces a strategic partnership or FDA designation. Short of those catalysts, this is interesting science without near-term commercial inflection.